* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Days Payable Chart
ASPHF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Days Payable distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Days Payable falls into.
Ascentage Pharma Group International Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a Days Payable of 746.28 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ascentage Pharma Group International and its competitors. This is 40% below median its historical median of 1,240.07. Over the past decade, Ascentage Pharma Group International's Days Payable has ranged from 218.75 to 5,126.12. According to the industry distribution chart, Ascentage Pharma Group International ranks #114 out of 708 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Ascentage Pharma Group International's Days Payable too high?
Ascentage Pharma Group International's current Days Payable of 746.28 is 40% below median its 10-year median of 1,240.07. Over the past 10 years, this metric has ranged from a low of 218.75 to a high of 5,126.12. The Biotechnology industry median Days Payable is 113.56. Ascentage Pharma Group International's value of 746.28 is 557.2% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #114 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #114 out of 708 companies for Days Payable. This places Ascentage Pharma Group International in the top 16% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Ascentage Pharma Group International's value of 746.28 is 557.2% above this benchmark. Historically, Ascentage Pharma Group International's own Days Payable has ranged from 218.75 to 5,126.12 over the past decade. While the company's 10-year median is 1,240.07 vs. the industry median of 113.56, Ascentage Pharma Group International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Days Payable of 746.28 is 557.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Days Payable is 746.28, which is 40% below median its own 10-year median of 1,240.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Days Payable is 746.28, which is 40% below median its 10-year median of 1,240.07 and 557.2% above the Biotechnology industry median of 113.56. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Days Payable is 746.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Days Payable: 746.28 (40% below median its 10-year median of 1,240.07)
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
Industry Position: 557.2% above the Biotechnology median (#114 of 708)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
